Recent antimalarial drug discovery has been a race to produce new medicines that
overcome emerging drug resistance, whilst considering safety and improving dosing …

The Malaria Drug Accelerator (MalDA) is a consortium of 15 leading scientific laboratories.
The aim of MalDA is to improve and accelerate the early antimalarial drug discovery process …

Compounds acting on multiple targets are critical to combating antimalarial drug resistance.
Here, we report that the human “mammalian target of rapamycin”(mTOR) inhibitor …

Malaria, which is caused by infection of red blood cells with Plasmodium parasites, can be
fatal in non-immune individuals if left untreated. The recent approval of the pre-erythrocytic …

Plasmepsin X (PMX) is an essential aspartyl protease controlling malaria parasite egress
and invasion of erythrocytes, development of functional liver merozoites (prophylactic …

Calcium signaling regulated by the cGMP-dependent protein kinase (PKG) controls key life
cycle transitions in the malaria parasite. However, how calcium is mobilized from …

The emergence and spread of Plasmodium falciparum resistance to first-line antimalarials
creates an imperative to identify and develop potent preclinical candidates with distinct …

Human malaria, caused by infection with Plasmodium parasites, remains one of the most
important global public health problems, with the World Health Organization reporting more …

Development of antimalarial compounds into clinical candidates remains costly and arduous
without detailed knowledge of the target. As resistance increases and treatment options at …

Surveillance of drug resistance and the discovery of novel targets—key objectives in the
fight against malaria—rely on identifying resistance-conferring mutations in Plasmodium …